Fig. 3: MMR by time point in patients not in MMR at screening.a
ASC asciminib, DAS dasatinib, IMA imatinib, MMR major molecular response (BCR::ABL1IS ≤ 0.1%), NIL nilotinib. aExcludes patients with atypical transcripts and those in MMR at baseline.
Fig. 3: MMR by time point in patients not in MMR at screening.a | Leukemia
